Tata Consultancy Services (TCS) is currently trading at Rs. 2601.85, up by 16.75 points or 0.65% from its previous closing of Rs. 2585.10 on the BSE.
The scrip opened at Rs. 2586.00 and has touched a high and low of Rs. 2612.95 and Rs. 2581.10 respectively. So far 6,235 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2707.40 on 06-Jun-2017 and a 52 week low of Rs. 2054.70 on 15-Nov-2016.
Last one week high and low of the scrip stood at Rs. 2612.95 and Rs. 2457.70 respectively. The current market cap of the company is Rs. 4,97,829.00 crore.
The promoters holding in the company stood at 73.57%, while Institutions and Non-Institutions held 22.26% and 4.18% respectively.
Tata Consultancy Services has launched Connected Clinical Trials (CCT), an innovative Software as a Service (SaaS) platform that enables pharmaceutical companies to significantly transform patient engagement in clinical trials and improve the efficiency and accountability of the clinical supply process.
CCT is part of TCS' Advanced Drug Development (ADD) suite that offers a wide range of cloud based clinical services, including Clinical Data Management, Metadata Management, Pharmacovigilance, and Data Analytics and Insights.
ADD is powered by a cognitive engine called 'Decision Fabric' that enables automation of complex business processes. ADD leverages the best of cloud architecture and intuitive user experience design in compliance with good clinical practice quality guidelines (GCP) and privacy regulations.
Tata Consultancy Services (TCS) is an IT services, consulting and business solutions organization that delivers real results to global business, ensuring a level of certainty no other firm can match. The company offers a consulting-led, integrated portfolio of IT, BPS, infrastructure, engineering and assurance services.